September 07, 2016
1 min read
Save

Trial Scorecard: TINSAL-CVD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers assessed whether targeting inflammation with salsalate vs. placebo reduced progression of noncalcified coronary artery plaque.

Trial Scorecard: TINSAL-CVD